曹丽娟，博士、研究员，博导。多靶标天然药物全国重点实验室青年骨干、省“333工程”三层次人才培养对象、原创药物研究院副院长。围绕代谢-免疫交互调控机制与新靶点发现研究、以及天然药物在代谢性疾病中的药效机制的研究，主持国家自然科学基金面上项目、重大新药创制子任务、重点研发计划子课题等6项。代表性成果发表在Nat Commun、Cell Metab、Cell Reports等杂志，共发表SCI论文30余篇、获授权发明专利5项，江苏省科学技术一等奖1项（第三完成人）。

  研究方向介绍：

1）疾病病程中代谢稳态调控规律与失衡机理研究：研究体内营养代谢、内源性活性分子代谢（胆汁酸、菌群代谢组、糖脂代谢等）稳态调控规律与机理，探索慢性肠炎、心血管疾病、代谢性疾病、感染性休克等病程中营养代谢与内源性活性分子代谢失衡机理及其与疾病的关联机制。

2）代谢免疫调节新机理及疾病新靶点发现与确证：研究慢性、炎症性、代谢性疾病病程中，内源性活性分子代谢免疫互调机理与调控靶点，发现并确证疾病干预新靶点，同步开展药物筛选与新药发现研究；研究不同疾病诊疗阶段下，营养代谢失衡规律与需求模式，探索慢病患者营养补充及生存质量提高方案。

3）基于靶点/表型的药物筛选与评价：构建靶点活性评价与药物筛选体系、建立多维度疾病表型组体系并开展高内涵药物筛选，以此开展创新药物研发工作。

☆ 特别提醒 ☆ ：

2026年硕士招生专业：药理学（学硕）、新药临床前评价（专硕）；

2026年博士招生专业：药理学。

欢迎致力于代谢免疫调控新机理及新靶点研究的广大学子报考！

E-mail：caolijuan0702@cpu.edu.cn

代表性论文：  

1.     Wanfeng Xu#, Yun Wang#, Shuang Cui#, Qiuling Zheng, Yanghao Lin, Qingqing Cui, Yuxin Xie, Yuming Zeng, Chuan Zhang, Yujie Li, Xin Jin, Minna Qin, Huiyong Sun*, Haiping Hao*, Lijuan Cao*. Methylcobalamin protects against liver failure via engaging gasdermin E. Nat Commun, 2025, 16(1): 1233.

Che Y#, Xu W#, Ding C#, He T, Xu X, Shuai Y, Huang H, Wu J, Wang Y, Wang C, Wang G, Cao L*, Hao H*. Bile acids target mitofusin 2 to differentially regulate innate immunity in physiological versus cholestatic conditions. Cell Rep. 2023 Jan 31;42(1):112011.

2.    Yun Wang#, Jiawei Wu#, Yu Hong#, Jiaying Zhu, Youcai Zhang, Jun Zhang, Chujie Ding, Yuan Che, Guangji Wang, Aiqin Jiang*, Haiping Hao*, Lijuan Cao*. Ginsenosides retard atherogenesis via remodelling host-microbiome metabolic homeostasis. Br J Pharmacol. 2024 Jun;181(12):1768-1792. 

3.     Wu J#, Zhang C#, He T, Zhang S, Wang Y, Xie Z, Xu W, Ding C, Shuai Y, Hao H*, Cao L*. Polyunsaturated fatty acids drive neutrophil extracellular trap formation in nonalcoholic steatohepatitis. Eur J Pharmacol. 2023 Feb 23:175618.

4.     Ding C#, Hong Y#, Che Y#, He T, Wang Y, Zhang S, Wu J, Xu W, Hou J, Hao H*, Cao L*. Bile acid restrained T cell activation explains cholestasis aggravated hepatitis B virus infection. FASEB J. 2022 Sep;36(9):e22468

5.     Xu WF#, Wang Y#, Huang H, Wu JW, Che Y, Ding CJ, Zhang Q, Cao WL*, Cao LJ*. Octreotide-based therapies effectively protect mice from acute and chronic gastritis. Eur J Pharmacol. 2022 Aug 5;928:174976.

6.     Xu W#, Che Y#, Zhang Q, Huang H, Ding C, Wang Y, Wang G, Cao L*, Hao H*. Apaf-1 Pyroptosome Senses Mitochondrial Permeability Transition. Cell Metab. 2021 Feb 2;33(2):424-436.e10.

7.     Xu WF#, Zhang Q#, Ding CJ, Sun HY, Che Y, Huang H, Wang Y, Wu JW, Hao HP*, Cao LJ*. Gasdermin E-derived caspase-3 Inhibitors Effectively Protect Mice From Acute Hepatic Failure. Acta Pharmacol Sin. 2021 Jan;42(1):68-76.

8.     Hao H^#, Cao L^# (co-first author), Jiang C^#, Che Y, Zhang S, Takahashi S, Wang G^*, Gonzalez FJ^*. Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metab. 2017 Apr 4;25(4):856-867.e5.

9.     Wang Y#, Wu J#, Zhu J, Ding C, Xu W, Hao H, Zhang J, Wang G*, Cao L*. Ginsenosides regulation of lysophosphatidylcholine profiles underlies the mechanism of Shengmai Yin in attenuating atherosclerosis. J Ethnopharmacol. 2021 Sep 15;277:114223.

10.   Zhou X^#, Cao L^# (co-first author), Jiang C^#, Xie Y, Chen X, Krausz KW, Qi Y, Sun L, Shah YM, Gonzalez FJ, Wang G*, Hao H*. PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun. 2014 Sep 3;5:4573.